Delivery Order SPE2DB25D7056-SPE2DB25FTNCB
Award Date 8/27/25
Potential Completion Date 8/28/25
Potential Value $2.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $134,719.00 on August 27, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $4,890.36 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 29, 2025, with completion targeted for September 2, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order for the hepatitis B vaccine product, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued as a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,699.20 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on open competition. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order is a child contract...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency awarded a $4,212.40 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of infection caused by...
- The Defense Logistics Agency awarded a delivery order valued at $113,419 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with completion targeted for August 13, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. HEPLISAV-B is a recombinant hepatitis B vaccine utilized by the Department of Defense for immunization programs...
- The Defense Logistics Agency awarded a delivery order valued at $54,285.04 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 21, 2025, with a completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a hepatitis B vaccine used to support military and federal healthcare immunization...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...